IMR Press / FBS / Volume 15 / Issue 2 / DOI: 10.31083/j.fbs1502007
Open Access Original Research
The Impact of Heparin Therapy in Deceased Donors on Early Graft Survival for Kidney and Liver Recipients: A Clinical Trial Study
Show Less
1 Medical Ethics and Law Research Center, Shaheed Beheshti University of Medical Sciences, 1985717443 Tehran, Iran
2 Organ Procurement Unit, Sina Hospital, Tehran University of Medical Sciences, 46911 Tehran, Iran
3 Cardiovascular Research Foundation of Southern California, Beverly Hills, CA 90210, USA
4 Southern California Medical Education Consortium, Temecula Valley Hospital, Universal Health System, Temecula, CA 92592, USA
5 Anesthesia, Critical Care and Pain Management Research Center, Tehran University of Medical Sciences, 1136746911 Tehran, Iran
6 Iranian Tissue Bank & Research Center, Tehran University of Medical Sciences, 1419733141 Tehran, Iran
*Correspondence: (Sanaz Dehghani)
Front. Biosci. (Schol Ed) 2023, 15(2), 7;
Submitted: 12 February 2023 | Revised: 19 April 2023 | Accepted: 8 June 2023 | Published: 25 June 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Background: Significant hemodynamic, hormonal, and metabolic impairment of a brain-dead organ donor is often associated with the deterioration of graft viability. This study aimed to compare the effect of heparin therapy as a therapeutic dose after brain death confirmation on early graft survival in kidney and liver recipients. Method and Materials: The deceased donors were sorted into two groups based on their D-dimer level. After confirming brain death, one group was given a heparin injection (case group), while the other group did not receive any heparin (control group). A total of 71 brain death donors and matched kidney and liver transplants were included in the case group. A total of 43 brain death donors and matched kidney and liver transplants were included in the control group. A total of 5000 units of heparin were administered every 6 hours to the deceased donor case group. Results: The mean age of the case and control groups were 36.27 ± 16.13 and 36.15 ± 18.45, respectively. An independent t test showed that there were no differences between the number of procured organs in both groups (p = 0.29). There was no significant difference between the graft survival rate and the doses of heparin injection to the liver recipients (p = 0.06). However, a significant difference was revealed between the graft survival rate and the dose of heparin injection (p = 0.004) in kidney recipients. Conclusions: The data suggest that administering low therapeutic doses of heparin to donors before organ donation may potentially prevent thrombosis and provide a protective benefit. We showed that heparin therapy had no significant effect on the number of donated organs and graft survival.

brain death
Back to top